Results (2814)
A registry-based non-interventional post-authorization safety study to evaluate the long-term safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis using the PEDISTAD registry: a cohort design
Argentina
Australia
Belgium
Brazil
Canada
China
Colombia
Denmark
France
Greece
Israel
Italy
Japan
Korea, Republic of
Mexico
Netherlands
Norway
Portugal
Russian Federation
Spain
United States
EU PAS number:
EUPAS1000000149
First published:
09/05/2024
StudyPlanned
An observational study of blinatumomab safety and effectiveness, utilisation, and treatment practices (20150136)
Austria
Czechia
Finland
France
Germany
Greece
Italy
Netherlands
Poland
Portugal
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS17848
First published:
09/05/2024
StudyOngoing
The Use of Oral Fluoroquinolones in Canada: Drug Utilization Study Update
Canada
EU PAS number:
EUPAS107333
First published:
08/05/2024
StudyOngoing
TAK-577-4005: Estimating Risk of Selected Adverse Events in Patients with Von Willebrand Disease Treated With VEYVONDI® (Vonicog Alfa; Recombinant Von Willebrand Factor)
Austria
Denmark
France
Germany
Netherlands
Norway
Sweden
United Kingdom (Northern Ireland)
EU PAS number:
EUPAS45617
First published:
08/05/2024
StudyFinalised
Population-based retrospective nested case-control study evaluating effectiveness of GARDASIL™ against adult-onset recurrent respiratory papillomatosis in Sweden (V503-088)
Sweden
EU PAS number:
EUPAS48452
First published:
08/05/2024
StudyOngoing
Antiplatelet Therapy during the First Year after Acute Coronary Syndrome in a Contemporary Italian Community of over 5 Million Subjects
Italy
EU PAS number:
EUPAS1000000154
First published:
08/05/2024
StudyFinalised
Population-based retrospective nested case-control study evaluating effectiveness of GARDASIL™ and GARDASIL 9™ against adult-onset recurrent respiratory papillomatosis in Denmark (V503-089)
Denmark
EU PAS number:
EUPAS50458
First published:
08/05/2024
StudyOngoing
Adakveo (crizanlizumab) PRegnancy outcomes Intensive Monitoring (PRIM) (Adakveo (crizanlizumab) PRIM)
Switzerland
EU PAS number:
EUPAS39412
First published:
08/05/2024
StudyOngoing
A Retrospective Analysis in Real World on Lymphocyte Reconstitution After Lymphopenia in Patients Treated by Tecfidera and Description of Management Strategies in France (Lympho-TEC)
France
EU PAS number:
EUPAS39505
First published:
08/05/2024
StudyFinalised
Association between use of direct oral anticoagulants (DOACs) and increased risk of interstitial lung disease
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000133
First published:
08/05/2024
StudyPlanned
A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy (SMA) - (RESTORE)
Argentina
Brazil
Chile
Greece
Ireland
Japan
Korea, Democratic People's Republic of
Poland
Portugal
Romania
Russian Federation
Taiwan
United States
EU PAS number:
EUPAS41853
First published:
08/05/2024
StudyOngoing
Multicenter Assessment of Treatment Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia (20180232) (Retrospective relapse/refractory AML outcomes)
Australia
Korea, Republic of
United States
EU PAS number:
EUPAS26165
First published:
08/05/2024
StudyOngoing
Cohort Study of Long-term Safety of Upadacitinib for the Treatment of Ulcerative Colitis and Crohn’s Disease in a Real-world Setting in Europe
Denmark
Spain
Sweden
EU PAS number:
EUPAS107124
First published:
08/05/2024
StudyPlanned
Morquio A Registry Study (MARS)
Australia
Austria
Belgium
Canada
Czechia
Denmark
France
Ireland
Italy
Malaysia
Netherlands
Poland
Portugal
Puerto Rico
Taiwan
United Kingdom
United States
EU PAS number:
EUPAS6835
First published:
08/05/2024
StudyOngoing
Pilot study on efficacy and safety of video-EEG monitoring to early identify newborns affected by mild hypoxic-ischemic encephalopathy who may benefit from therapeutic hypothermia: correlation between early video-EEG monitoring and 24-months neurodevelopmental outcome in treated and non-treated newborns.
Italy
EU PAS number:
EUPAS106301
First published:
08/05/2024
StudyPlanned
A Non-Interventional Post-Authorization Safety Study (NI-PASS) as an effectiveness check of a Patient Card for Padcev™
France
Germany
Italy
Poland
Spain
Sweden
Switzerland
EU PAS number:
EUPAS104456
First published:
07/05/2024
StudyOngoing
A post-licensure prospective observational registry study in real-world Taiwanese cancer patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) genes
Taiwan
EU PAS number:
EUPAS33807
First published:
07/05/2024
StudyOngoing
Post-marketing study to assess the effectiveness of doravirine-included in highly active antiretroviral therapy (HAART) in HIV-1 infected adult Chinese patients (MK-1439-088)
China
EU PAS number:
EUPAS103993
First published:
07/05/2024
StudyOngoing
A Retrospective Cohort Study to Characterize Patient Characteristics and Treatment Outcomes Among Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) in the French Epidemiological Strategy and Medical Economics Advanced or Metastatic Lung Cancer (ESME-AMLC) Database (20190402)
France
EU PAS number:
EUPAS40706
First published:
07/05/2024
StudyOngoing
A Multi-Center, Observational Study to Evaluate the Long-Term Safety of Subcutaneous Injections of Palynziq® (pegvaliase) in Subjects with Phenylketonuria (PALace)
Germany
Italy
United States
EU PAS number:
EUPAS34992
First published:
07/05/2024
StudyOngoing
Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
United States
EU PAS number:
EUPAS45952
First published:
06/05/2024
StudyOngoing
Prospective observational study to assess the long term safety profile of venetoclax in a Swedish cohort of Chronic Lymphocytic Leukaemia (CLL) patients
Sweden
EU PAS number:
EUPAS19010
First published:
06/05/2024
StudyOngoing
A registry-based cohort study of Spinal Muscular Atrophy (SMA) disease to describe the natural history of SMA, the evolution of SMA care management and disease progression considering new disease modifying therapies (DMTs).
Austria
Belgium
Czechia
Germany
Ireland
Slovakia
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS50476
First published:
04/05/2024
StudyOngoing
Safety and effectiveness of COVID-19 maternal immunisation: An update of available evidence
Brazil
Canada
Israel
Norway
Qatar
Romania
Sweden
United Kingdom
United States
EU PAS number:
EUPAS47697
First published:
03/05/2024
StudyFinalised
DARWIN EU® Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer
Germany
Spain
United Kingdom
EU PAS number:
EUPAS1000000080
First published:
03/05/2024
StudyOngoing
Prospective cohort study to monitor the emergence of SARSCoV-2 spike viral variants in immunocompromised nonhospitalised patients exposed to sotrovimab in Great Britain: LUNAR study (218407)
United Kingdom
EU PAS number:
EUPAS46386
First published:
03/05/2024
StudyFinalised
A Rapid Surveillance and Cohort Post-Marketing Safety Study to Evaluate the Safety of Respiratory Syncytial Virus Vaccine (ABRYSVO™) Exposure During Pregnancy in the United States (C3671027)
United States
EU PAS number:
EUPAS1000000115
First published:
03/05/2024
StudyOngoing
A retrospective analysis of overall response and survival to 1st+ salvage therapy in T-cell and 2nd+ salvage therapy in B-cell pediatric acute lymphoblastic leukemia (20180065) (Retrospective pediatric ALL retrospective response)
Australia
Canada
Germany
Italy
United States
EU PAS number:
EUPAS27121
First published:
03/05/2024
StudyOngoing
Association between opioid use and the development of diverticulitis (Opioids Diverticulitis)
Canada
United Kingdom
United States
EU PAS number:
EUPAS104164
First published:
03/05/2024
StudyOngoing
CharacTeristics of treAtment response to hIgh dose ICS/LABA vs. Medium or high dOse ICS/LABA + LAMA in patients with uncontRolled moderate to severe asthma on medium dose ICS/LABA - TAILOR study
Denmark
Italy
Netherlands
United Kingdom
EU PAS number:
EUPAS39039
First published:
02/05/2024
StudyOngoing
Ranitidine and other histamine H2-receptor antagonists – a drug utilisation study
Belgium
France
Germany
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS33397
First published:
02/05/2024
StudyFinalised
Drug utilisation studies using data mapped to the OMOP Common Data Model: a proof of concept study assessing respiratory drug use in patients with asthma or COPD
Netherlands
United Kingdom
United States
EU PAS number:
EUPAS41726
First published:
02/05/2024
StudyOngoing
Prospective Registry-Based Study of the Long-Term Safety of Odeevixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Austria
Belgium
Brazil
Canada
China
France
Hungary
India
Ireland
Israel
Italy
Netherlands
Poland
Portugal
Slovenia
South Africa
Spain
Sweden
Switzerland
Türkiye
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS106243
First published:
02/05/2024
StudyOngoing
TAK-906-5003: Real-world Evidence on Diagnosed Gastroparesis in Europe: Multi-database Observational Epidemiological Study
Finland
Spain
EU PAS number:
EUPAS37806
First published:
02/05/2024
StudyOngoing
Retrospective cohort study evaluating effectiveness of GARDASIL™ against adult-onset recurrent respiratory papillomatosis in Norway
Norway
EU PAS number:
EUPAS50387
First published:
02/05/2024
StudyOngoing
GENEr8-COAS: A Non-Interventional, Multi-National, Longitudinal Study of Patients Treated with ROCTAVIAN™ (valoctocogene roxaparvovec) (GENEr8-COAS Observational Cohort Study)
Germany
Italy
United States
EU PAS number:
EUPAS49071
First published:
02/05/2024
StudyPlanned
Kesimpta (ofatumumab) pregnancy and infant safety study using real world data
Denmark
Sweden
United States
EU PAS number:
EUPAS106133
First published:
02/05/2024
StudyPlanned
Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine − CLARION
Australia
Belgium
Denmark
Finland
France
Germany
Italy
Netherlands
Norway
Spain
Sweden
Switzerland
Türkiye
United Kingdom
EU PAS number:
EUPAS24484
First published:
02/05/2024
StudyOngoing
Antipsychotics in pregnancy and the risk of adverse pregnancy outcomes - a nationwide study
Norway
EU PAS number:
EUPAS1000000134
First published:
02/05/2024
StudyPlanned
Survey to Assess the Effectiveness of Ponvory® Educational Materials for Additional Risk Minimization Measures in the European Union
Austria
Belgium
Czechia
France
Germany
Italy
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS107763
First published:
02/05/2024
StudyOngoing